Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

3.95
-0.0300-0.75%
Post-market: 3.93-0.0200-0.51%16:51 EDT
Volume:313.95K
Turnover:1.25M
Market Cap:304.60M
PE:-3.97
High:4.07
Open:4.02
Low:3.94
Close:3.98
Loading ...

Q4 2024 Corvus Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
26 Mar

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit

Simply Wall St.
·
26 Mar

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating

MT Newswires Live
·
26 Mar

Corvus Pharmaceuticals : Oppenheimer Raises Target Price to $15 From $14

THOMSON REUTERS
·
26 Mar

Corvus Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Analysts Are Bullish on These Healthcare Stocks: Artiva Biotherapeutics, Inc. (ARTV), Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
26 Mar

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
26 Mar

Corvus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Mar

Corvus Pharmaceuticals: Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 to Be Presented in May

THOMSON REUTERS
·
26 Mar

Corvus Pharmaceuticals Q4 Operating Expenses USD 8.105 Million

THOMSON REUTERS
·
26 Mar

Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
22 Mar

Corvus announces presentation of data from Phase 1/1b trial of soquelitinib

TIPRANKS
·
20 Mar

Corvus Pharmaceuticals Announces Presentation of Additional Data From the Phase 1/1B Clinical Trial of Soquelitinib for Patients With T Cell Lymphoma

THOMSON REUTERS
·
20 Mar

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

GlobeNewswire
·
20 Mar

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire
·
20 Mar

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

GlobeNewswire
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Corvus Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Buy Recommendation for Corvus Pharmaceuticals Driven by Soquelitinib’s Promising Trial Results and Strong Financial Position

TIPRANKS
·
14 Jan

BRIEF-Corvus Pharmaceuticals Announces Data From Cohort 2 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Reuters
·
13 Jan